Transcription regulation and human diseases

Swiss Medical Weekly

Volumn 134, Issue 39-40, 2004, Pages 571-579

  Villard, Jean ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Cancer; Chromatin structure; Genetic diseases; MHC class II deficiency; Promoter; Transcription factors

Indexed keywords

BLOOD CLOTTING FACTOR 9; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CIS ACTING ELEMENT; CYTOKINE; DNA; HEPATOCYTE NUCLEAR FACTOR 4; HLA A1 ANTIGEN; HLA DQ ANTIGEN; HYBRID PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN P53; RETINOBLASTOMA PROTEIN; RETINOIC ACID RECEPTOR ALPHA; RNA; T LYMPHOCYTE RECEPTOR; TRANS ACTING FACTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA 1; TUMOR NECROSIS FACTOR ALPHA; WT1 PROTEIN; ZINC FINGER PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BINDING SITE; CANCER; CHROMATIN STRUCTURE; CHROMOSOME TRANSLOCATION; DNA BINDING; FAMILIAL CANCER; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC DISORDER; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; HEMOGLOBINOPATHY; HEMOPHILIA B; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN GENE; LEUKEMIA; MATURITY ONSET DIABETES MELLITUS; MYOCLONUS EPILEPSY; NEPHROBLASTOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; PROMOTER REGION; RECEPTOR GENE; RETINOBLASTOMA; REVIEW; TATA BOX; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; X CHROMOSOME LINKED DISORDER;

EID: 9144238416     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Sauer F, Tjian R. Mechanisms of transcriptional activation: differences and similarities between yeast, Drosophila, and man. Curr Opin Genet Dev 1997;7:176-81.
2. Maniatis T, Goodbourn S, Fischer JA. Regulation of inducible and tissue-specific gene expression. Science 1987;236:1237-45.
3. Kingston RE, Bunker CA, Imbalzano AN. Repression and activation by multiprotein complexes that alter chromatin structure. Genes Dev 1996;10:905-20.
4. Emerson BM. Specificity of gene regulation. Cell 2002;109: 267-70.
5. Mitchell PJ, Tjian R. Transcriptional regulation in mammalian cells by sequence-specific DNA binding proteins. Science 1989;245:371-8.
6. Young RA. RNA polymerase II. Annu Rev Biochem 1991;60: 689-715.
7. Koleske AJ, Young RA. An RNA polymerase II holoenzyme responsive to activators. Nature 1994;368:466-9.
8. Renkawitz R. Transcriptional repression in eukaryotes. Trends Genet 1990;6:192-7.
9. Levine M, Tjian R. Transcription regulation and animal diversity. Nature 2003;424:147-51.
10. Crossley M, Orkin SH. Regulation of the beta-globin locus. Curr Opin Genet Dev 1993;3:232-7.
11. Sharpe JA, Chan-Thomas PS, Lida J, Ayyub H, Wood WG, Higgs DR. Analysis of the human alpha globin upstream regulatory element (HS-40) in transgenic mice. EMBO J 1992;11: 4565-72.
12. Bentley DL. Regulation of transcriptional elongation by RNA polymerase II. Curr Opin Genet Dev 1995;5:210-6.
13. Roeder RG. Role of general and gene-specific cofactors in the regulation of eukaryotic transcription. Cold Spring Harb Symp Quant Biol 1998;63:201-18.
14. Pabo CO, Sauer RT. Transcription factors: structural families and principles of DNA recognition. Annu Rev Biochem 1992; 61:1053-95.
15. Kim YJ, Bjorklund S, Li Y, Sayre MH, Kornberg RD. A multiprotein mediator of transcriptional activation and its interaction with the C-terminal repeat domain of RNA polymerase II. Cell 1994;77:599-608.
16. Arany Z, Sellers WR, Livingston DM, Eckner R. E1A-associated p300 and CREB-associated CBP belong to a conserved family of coactivators. Cell 1994;77:799-800.
17. Korzus E, Torchia J, Rose DW, Xu L, Kurokawa R, McInerney EM, et al. Transcription factor-specific requirements for coactivators and their acetyltransferase functions. Science 1998;279:703-7.
18. Crossley M, Ludwig M, Stowell KM, De Vos P, Olek K, Brownlee GG. Recovery from hemophilia B Leyden: an androgen-responsive element in the factor IX promoter. Science 1992; 257:377-9.
19. Crossley M, Brownlee GG. Disruption of a C/EBP binding site in the factor IX promoter is associated with haemophilia B. Nature 1990;345:444-6.
20. Martin DI, Tsai SF, Orkin SH. Increased gamma-globin expression in a nondeletion HPFH mediated by an erythroid-specific DNA-binding factor. Nature 1989;338:435-8.
21. Hardison R, Slightom JL, Gumucio DL, Goodman M, Stojanovic N, Miller W. Locus control regions of mammalian beta-globin gene clusters: combining phylogenetic analyses and experimental results to gain functional insights. Gene 1997; 205:73-94.
22. Faustino P, Lavinha J, Marini MG, Moi P. beta-Thalassemia mutation at -90CÆT impairs the interaction of the proximal CACCC box with both erythroid and nonerythroid factors. Blood 1996;88:3248-9.
23. Lalioti MD, Scott HS, Buresi C, Rossier C, Bottani A, Morris MA, et al. Dodecamer repeat expansion in cystatin B gene in progressive myoclonus epilepsy. Nature 1997;386:847-51.
24. Morzycka-Wroblewska E, Munshi A, Ostermayer M, Harwood JI, Kagnoff MF. Differential expression of HLA-DQA1 alleles associated with promoter polymorphism. Immunogenetics 1997;45:163-70.
25. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997;94:3195-9.
26. Martin MP, Dean M, Smith MW, Winkler C, Gerrard B, Michael NL, et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 1998;282:1907-11.
27. Latchman DS. Transcription-factor mutations and disease. N Engl J Med 1996;334:28-33.
28. Sanchez-Garcia I. Consequences of chromosomal abnormalities in tumour development. Annu Rev Genet 1997;31:429-53.
29. Gibbons RJ, Picketts DJ, Villard L, Higgs DR. Mutations in a putative global transcriptional regulator cause X-linked mental retardation with alpha-thalassemia (ATR-X syndrome). Cell 1995;80:837-45.
30. Liu J, Akoulitchev S, Weber A, Ge H, Chuikov S, Libutti D, et al. Defective interplay of activators and repressors with TFIH in xeroderma pigmentosum. Cell 2001;104:353-63.
31. Lehmann AR. The xeroderma pigmentosum group D (XPD) gene: one gene, two functions, three diseases. Genes Dev 2001; 15:15-23.
32. Giles RH, Peters DJ, Breuning MH. Conjunction dysfunction: CBP/p300 in human disease. Trends Genet 1998;14:178-83.
33. Hartzog GA, Winston F. Nucleosomes and transcription: recent lessons from genetics. Curr Opin Genet Dev 1997;7: 192-8.
34. Andersen B, Rosenfeld MG. Pit-1 determines cell types during development of the anterior pituitary gland. A model for transcriptional regulation of cell phenotypes in mammalian organogenesis. J Biol Chem 1994;269:29335-8.
35. Radovick S, Cohen LE, Wondisford FE. The molecular basis of hypopituitarism. Horm Res 1998;49(Suppl 1):30-6.
36. de Kok YJ, van der Maarel SM, Bitner-Glindzicz M, Huber I, Monaco AP, Malcolm S, et al. Association between X-linked mixed deafness and mutations in the POU domain gene POU3F4. Science 1995;267:685-8.
37. Meier CA. Regulation of gene expression by nuclear hormone receptors. J Recept Signal Transduct Res 1997;17:319-35.
38. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell 1995;83:841-50.
39. Ferlini A, Patrosso MC, Guidetti D, Merlini L, Uncini A, Ragno M, et al. Androgen receptor gene (CAG)n repeat analysis in the differential diagnosis between Kennedy disease and other motoneuron disorders. Am J Med Genet 1995;55:105-11.
40. Herman WH, Fajans SS, Ortiz FJ, Smith MJ, Sturis J, Bell GI, et al. Abnormal insulin secretion, not insulin resistance, is the genetic or primary defect of MODY in the RW pedigree. Diabetes 1994;43:40-6.
41. Yamagata K, Furuta H, Oda N, Kaisaka PJ, Menzel S, Cos NJ, et al. Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1). Nature 1996; 384:458-60.
42. Yamagata K, Oda N, Kaisaki PJ, Menzel S, Furuta H, Vaxillaire M, et al. Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3). Nature 1996;384:455-8.
43. Stoffers DA, Ferrer J, Clarke WL, Habener JF. Early-onset type-II diabetes mellitus (MODY4) linked to IPF1. Nat Genet 1997;17:138-9.
44. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. The Finnish-German APECED Consortium. Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy. Nat Genet 1997;17:399-403.
45. Reith W, Mach B. The bare lymphocyte syndrome and the regulation of MHC expression. Annu Rev Immunol 2001;19: 331-73.
46. Villard J, Masternak K, Lisowska-Grospierre B, Fischer A, Reith W. MHC class II deficiency: a disease of gene regulation. Medicine 2001;80:405-18.
47. Nebert DW. Transcription factors and cancer: an overview. Toxicology 2002;181-182:131-41.
48. Rabbitts TH. Chromosomal translocations in human cancer. Nature 1994;372:143-9.
49. Koken MH, Puvion-Dutilleul F, Guillemin MC, Viron A, Linares-Cruz G, Stuurman N, et al. The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO J 1994;13:1073-83.
50. Gerald WL, Rosai J, Ladanyi M. Characterization of the genomic breakpoint and chimeric transcripts in the EWS-WT1 gene fusion of desmoplastic small round cell tumor. Proc Natl Acad Sci USA 1995;92:1028-32.
51. Malkin D. Germline p53 mutations and heritable cancer. Annu Rev Genet 1994;28:443-65.
52. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002;2:103-12.